81 related articles for article (PubMed ID: 30885432)
21. Mutagenesis study to disrupt electrostatic interactions on the twofold symmetry interface of Escherichia coli bacterioferritin.
Zhang Y; Wang L; Ardejani MS; Aris NF; Li X; Orner BP; Wang F
J Biochem; 2015 Dec; 158(6):505-12. PubMed ID: 26115686
[TBL] [Abstract][Full Text] [Related]
22. Improved Catenated Structures of Bovine Peroxiredoxin III F190L Reveal Details of Ring-Ring Interactions and a Novel Conformational State.
Cao Z; McGow DP; Shepherd C; Lindsay JG
PLoS One; 2015; 10(4):e0123303. PubMed ID: 25906064
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 A resolution.
Schröder E; Littlechild JA; Lebedev AA; Errington N; Vagin AA; Isupov MN
Structure; 2000 Jun; 8(6):605-15. PubMed ID: 10873855
[TBL] [Abstract][Full Text] [Related]
24. Proteomics viewed on stress response of thermophilic bacterium Bacillus stearothermophilus TLS33.
Topanurak S; Sinchaikul S; Phutrakul S; Sookkheo B; Chen ST
Proteomics; 2005 Sep; 5(14):3722-30. PubMed ID: 16127733
[TBL] [Abstract][Full Text] [Related]
25. In vivo analysis of the 2-Cys peroxiredoxin oligomeric state by two-step FRET.
Seidel T; Seefeldt B; Sauer M; Dietz KJ
J Biotechnol; 2010 Sep; 149(4):272-9. PubMed ID: 20615439
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the decameric structure of peroxiredoxin-II by transmission electron microscopy and X-ray crystallography.
Harris JR; Schröder E; Isupov MN; Scheffler D; Kristensen P; Littlechild JA; Vagin AA; Meissner U
Biochim Biophys Acta; 2001 Jun; 1547(2):221-34. PubMed ID: 11410278
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure and solution NMR dynamics of a D (type II) peroxiredoxin glutaredoxin and thioredoxin dependent: a new insight into the peroxiredoxin oligomerism.
Echalier A; Trivelli X; Corbier C; Rouhier N; Walker O; Tsan P; Jacquot JP; Aubry A; Krimm I; Lancelin JM
Biochemistry; 2005 Feb; 44(6):1755-67. PubMed ID: 15697201
[TBL] [Abstract][Full Text] [Related]
28. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin.
Chae HZ; Kim HJ; Kang SW; Rhee SG
Diabetes Res Clin Pract; 1999 Sep; 45(2-3):101-12. PubMed ID: 10588361
[TBL] [Abstract][Full Text] [Related]
29. The molecular interactions that stabilize RNA tertiary structure: RNA motifs, patterns, and networks.
Butcher SE; Pyle AM
Acc Chem Res; 2011 Dec; 44(12):1302-11. PubMed ID: 21899297
[TBL] [Abstract][Full Text] [Related]
30. Engineering discrete stacks of aromatic molecules.
Klosterman JK; Yamauchi Y; Fujita M
Chem Soc Rev; 2009 Jun; 38(6):1714-25. PubMed ID: 19587964
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization and functional analysis of a peroxiredoxin 1 cDNA from golden pompano (Trachinotus ovatus).
Wang L; Guo H; Zhang N; Ma Z; Jiang S; Zhang D
Dev Comp Immunol; 2015 Aug; 51(2):261-70. PubMed ID: 25889122
[TBL] [Abstract][Full Text] [Related]
32. Kinetic analysis of structural influences on the susceptibility of peroxiredoxins 2 and 3 to hyperoxidation.
Poynton RA; Peskin AV; Haynes AC; Lowther WT; Hampton MB; Winterbourn CC
Biochem J; 2016 Feb; 473(4):411-21. PubMed ID: 26614766
[TBL] [Abstract][Full Text] [Related]
33. Cloning, expression of a peroxiredoxin gene from Acinetobacter sp. SM04 and characterization of its recombinant protein for zearalenone detoxification.
Yu Y; Wu H; Tang Y; Qiu L
Microbiol Res; 2012 Mar; 167(3):121-6. PubMed ID: 21885267
[TBL] [Abstract][Full Text] [Related]
34. Formation of supramolecular protein structures on gold surfaces.
Domigan LJ; Ashmead H; Dimartino S; Malmstrom J; Grant Pearce F; Blunt M; Williams DE; Gerrard JA
Biointerphases; 2017 Nov; 12(4):04E405. PubMed ID: 29141412
[TBL] [Abstract][Full Text] [Related]
35. An antioxidant redox system in the nucleus of wheat seed cells suffering oxidative stress.
Pulido P; Cazalis R; Cejudo FJ
Plant J; 2009 Jan; 57(1):132-45. PubMed ID: 18786001
[TBL] [Abstract][Full Text] [Related]
36. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome.
Kim SH; Fountoulakis M; Cairns N; Lubec G
J Neural Transm Suppl; 2001; (61):223-35. PubMed ID: 11771746
[TBL] [Abstract][Full Text] [Related]
37. Peroxiredoxin II is essential for preventing hemolytic anemia from oxidative stress through maintaining hemoglobin stability.
Han YH; Kim SU; Kwon TH; Lee DS; Ha HL; Park DS; Woo EJ; Lee SH; Kim JM; Chae HB; Lee SY; Kim BY; Yoon DY; Rhee SG; Fibach E; Yu DY
Biochem Biophys Res Commun; 2012 Sep; 426(3):427-32. PubMed ID: 22960070
[TBL] [Abstract][Full Text] [Related]
38. Engineering an intertwined form of CD2 for stability and assembly.
Murray AJ; Head JG; Barker JJ; Brady RL
Nat Struct Biol; 1998 Sep; 5(9):778-82. PubMed ID: 9731771
[TBL] [Abstract][Full Text] [Related]
39. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis.
Morinaka A; Funato Y; Uesugi K; Miki H
Oncogene; 2011 Oct; 30(40):4208-18. PubMed ID: 21516123
[TBL] [Abstract][Full Text] [Related]
40. Structural and biochemical analyses reveal ubiquitin C-terminal hydrolase-L1 as a specific client of the peroxiredoxin II chaperone.
Lee SP; Park CM; Kim KS; Kim E; Jeong M; Shin JY; Yun CH; Kim K; Chock PB; Chae HZ
Arch Biochem Biophys; 2018 Feb; 640():61-74. PubMed ID: 29339092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
